Figure 5

Combined prognostic and biologic analysis of germinal-center-B-cell-like (GCB) and activated-B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) with or without MYC translocation (MYC-R) and/or Myc overexpression (Myc^high) in the current study cohort. (a) GCB-DLBCL patients with both MYC translocation and Myc overexpression (MYC-R⁺/Myc^high) had significantly worse overall survival compared with GCB-DLBCL patients with low Myc expression (Myc^low) and Myc^high patients without MYC translocation (MYC-R⁻/Myc^high). The MYC-R⁻/Myc^high group did not have significant poorer survival compared with the Myc^low group. (b) Genes significantly differentially expressed between MYC-R⁺/Myc^high GCB-DLBCL patients and Myc^low GCB-DLBCL patients (false discovery rate <0.01, fold change >2.38). (c) Genes significantly differentially expressed between MYC-R⁺/Myc^high and MYC-R⁻/Myc^high GCB-DLBCL patients (false discovery rate <0.30). (d) Only MYC-R⁻/Myc^high but not MYC-R⁺/Myc^high ABC-DLBCL patients had significantly OS compared with Myc^low ABC-DLBCL patients. (e) Genes significantly differentially expressed between MYC-R⁻/Myc^high ABC-DLBCL and Myc^low ABC-DLBCL (false discovery rate <0.01, fold change >1.57). (f) Genes significantly differentially expressed between ABC and GCB subtypes of MYC-R⁺ DLBCL. (g) MYC-R⁺/Myc^high GCB-DLBCL showed trend towards worse progression-free survival compared with MYC-R⁻/Myc^high ABC-DLBCL patients with a borderline P-value. (h) Genes significantly differentially expressed between MYC-R⁺ and MYC-R⁻DLBCL (false discovery rate <0.01, fold change >1.66). (i) Genes significantly differentially expressed between MYC-R⁺/Myc^high and MYC-R⁻/Myc^high DLBCL (false discovery rate <0.01, fold change >2.05). ABC, activated-B-cell-like; GCB, germinal-center-B-cell-like; Myc^high, high Myc protein expression; Myc^low, low Myc protein expression; MYC-R⁺: MYC rearrangement-positive; MYC-R⁻, MYC rearrangement-negative.